极早产儿支气管肺发育不良或死亡风险对氢化可的松疗效异质性的影响:NICHD新生儿研究网络试验的二次分析
该研究为NICHD新生儿研究网络氢化可的松试验的二次事后分析,纳入799例胎龄小于30周、机械通气至少7天、日龄14-28天的极早产儿,随机接受10天氢化可的松或安慰剂治疗。采用NICHD新生儿BPD结局估算器评估基线2-3级BPD或死亡风险,平均风险为54%(范围18%-84%)。结果显示,治疗组与基线风险在相对或绝对尺度上的交互作用均无统计学意义:2-3级BPD或死亡的相对风险从四分位1的1.13(95%CI 0.82-1.55)到四分位4的0.94(95%CI 0.81-1.09);中重度NDI或死亡的相对风险从四分位1的1.04(95%CI 0.80-1.36)到四分位4的0.99(95%CI 0.80-1.22)。结论认为,氢化可的松与安慰剂的效果差异未因基线2-3级BPD或死亡风险而明显改变。
要点
- 在799例极早产儿中,氢化可的松对2-3级BPD或死亡的效果未因基线风险而异(交互作用无统计学意义)。
- 2-3级BPD或死亡的相对风险:四分位1为1.13(95%CI 0.82-1.55),四分位4为0.94(95%CI 0.81-1.09)。
- 中重度NDI或死亡的相对风险:四分位1为1.04(95%CI 0.80-1.36),四分位4为0.99(95%CI 0.80-1.22)。
- 研究人群平均基线2-3级BPD或死亡风险为54%(范围18%-84%)。
- 该分析为二次事后分析,不能据此推荐按基线风险选择氢化可的松治疗。
适用人群与场景
- 胎龄小于30周、机械通气至少7天(包括入组时)且日龄14-28天的极早产儿,来自美国19个学术中心。
- 排除标准未在原文中报告。
诊断标准与关键阈值
- 使用NICHD新生儿BPD结局估算器评估基线2-3级BPD或死亡风险。
处置流程与药物剂量
- infants randomized to 10 days of hydrocortisone or placebo treatment.
研究设计与关键结果
- 研究类型:随机对照试验的二次事后分析;样本量799例(男421例,52.7%);平均(SD)胎龄24.9(1.5)周,平均(SD)出生体重715(167)g。
- 干预与对照:10天氢化可的松 vs 安慰剂。
- 主要终点:2-3级BPD或死亡;治疗组与基线风险的交互作用在相对或绝对尺度上均无统计学意义,效应量从四分位1的相对风险1.13(95%CI 0.82-1.55)到四分位4的0.94(95%CI 0.81-1.09)。
- 关键次要终点:中重度NDI或死亡;交互作用在相对或绝对尺度上均无统计学意义,效应量从四分位1的相对风险1.04(95%CI 0.80-1.36)到四分位4的0.99(95%CI 0.80-1.22)。
- 研究人群平均估计基线2-3级BPD或死亡风险为54%(范围18%-84%)。
证据类型、等级与局限
- 证据类型:随机对照试验的二次事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论未据此给出推荐。
指南或共识出处
- NICHD新生儿研究网络氢化可的松试验(ClinicalTrials.gov Identifier: NCT01353313)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Extremely preterm infants who develop bronchopulmonary dysplasia (BPD) are at a higher risk for adverse pulmonary and neurodevelopmental outcomes. In the National Institute of Child Health and Human Development Neonatal Research Network (NICHD NRN) Hydrocortisone Trial, hydrocortisone neither reduced rates of BPD or death nor increased rates of neurodevelopmental impairment (NDI) or death.
OBJECTIVE: To determine whether estimated risk for grades 2 to 3 BPD or death is associated with the effect of hydrocortisone on the composite outcomes of (1) grades 2 to 3 BPD or death and (2) moderate or severe NDI or death.
DESIGN, SETTING, AND PARTICIPANTS: This secondary post hoc analysis used data from the NICHD NRN Hydrocortisone Trial, which was a double-masked, placebo-controlled, randomized clinical trial conducted in 19 US academic centers. The NICHD HRN Hydrocortisone Trial enrolled infants born at a gestational age of less than 30 weeks who received mechanical ventilation for at least 7 days, including at the time of enrollment, and who were aged 14 to 28 postnatal days. Infants were enrolled between August 22, 2011, and February 4, 2018, with follow-up between 22 and 26 months of corrected age completed on March 29, 2020. Data were analyzed from September 13, 2021, to March 25, 2023.
INTERVENTION: Infants were randomized to 10 days of hydrocortisone or placebo treatment.
MAIN OUTCOMES AND MEASURES: Infants' baseline risk of grades 2 to 3 BPD or death was estimated using the NICHD Neonatal BPD Outcome Estimator. Differences in absolute and relative treatment effects by baseline risk were evaluated using interaction terms in models fitted to the efficacy outcome of grades 2 to 3 BPD or death and the safety outcome of moderate or severe NDI or death by follow-up.
RESULTS: Among the 799 infants included in the analysis (421 boys [52.7%]), the mean (SD) gestational age was 24.9 (1.5) weeks, and the mean (SD) birth weight was 715 (167) g. The mean estimated baseline risk for grades 2 to 3 BPD or death was 54% (range, 18%-84%) in the study population. The interaction between treatment group and baseline risk was not statistically significant on a relative or absolute scale for grades 2 to 3 BPD or death; the size of the effect ranged from a relative risk of 1.13 (95% CI, 0.82-1.55) in quartile 1 to 0.94 (95% CI, 0.81-1.09) in quartile 4. Similarly, the interaction between treatment group and baseline risk was not significant on a relative or absolute scale for moderate or severe NDI or death; the size of the effect ranged from a relative risk of 1.04 (95% CI, 0.80-1.36) in quartile 1 to 0.99 (95% CI, 0.80-1.22) in quartile 4.
CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, the effect of hydrocortisone vs placebo was not appreciably modified by baseline risk for grades 2 to 3 BPD or death.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01353313.
参考来源
- Gentle SJ, Rysavy MA, Li L, et al. Heterogeneity of Treatment Effects of Hydrocortisone by Risk of Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants in the National Institute of Child Health and Human Development Neonatal Research Network Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37256621. doi:10.1001/jamanetworkopen.2023.15315
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。